Aevitas Therapeutics
New York
New York
United States
About Aevitas Therapeutics
Aevitas Therapeutics, Inc. (“Aevitas”), develops novel gene therapy approaches for complement-mediated diseases. Aevitas is a subsidary company of Fortress Biotech Inc.4 articles about Aevitas Therapeutics
-
Aevitas Therapeutics, a Fortress Biotech Subsidiary, Announces Asset Purchase Agreement with 4D Molecular Therapeutics for World-Wide Rights to Aevitas’ Short-Form Human Complement Factor H
4/24/2023
Aevitas Therapeutics, Inc. today announced the execution of an asset purchase agreement for 4DMT to acquire Aevitas’ proprietary rights to its short-form human complement factor H (“sCFH”) asset for the treatment of complement-mediated diseases.
-
BioSpace Movers & Shakers, Feb. 26
2/26/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Aevitas Therapeutics Appoints Markus Peters, Ph.D., M.Sc., as Chief Executive Officer
2/22/2021
Aevitas Therapeutics, Inc. (“Aevitas”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) partner company focused on the development of novel gene therapy approaches for complement-mediated diseases, today announced the appointment of Markus Peters, Ph.D., M.Sc., as President and Chief Executive Officer.
-
Fortress Biotech Forms New Subsidiary, Aevitas Therapeutics, To Develop Novel AAV Gene Therapy Treatments For Complement-Mediated Diseases
8/14/2017